<?xml version='1.0' encoding='utf-8'?>
<document id="22162508"><sentence text="No pharmacokinetic interaction between lacosamide and valproic acid in healthy volunteers."><entity charOffset="39-49" id="DDI-PubMed.22162508.s1.e0" text="lacosamide" /><entity charOffset="54-67" id="DDI-PubMed.22162508.s1.e1" text="valproic acid" /><pair ddi="false" e1="DDI-PubMed.22162508.s1.e0" e2="DDI-PubMed.22162508.s1.e0" /><pair ddi="false" e1="DDI-PubMed.22162508.s1.e0" e2="DDI-PubMed.22162508.s1.e1" /></sentence><sentence text="Two open-label, randomized, multiple-dose clinical studies evaluated the potential for pharmacokinetic interaction between the antiepileptic drugs lacosamide and valproic acid"><entity charOffset="147-157" id="DDI-PubMed.22162508.s2.e0" text="lacosamide" /><entity charOffset="162-175" id="DDI-PubMed.22162508.s2.e1" text="valproic acid" /><pair ddi="false" e1="DDI-PubMed.22162508.s2.e0" e2="DDI-PubMed.22162508.s2.e0" /><pair ddi="false" e1="DDI-PubMed.22162508.s2.e0" e2="DDI-PubMed.22162508.s2.e1" /></sentence><sentence text=" The influence of lacosamide on valproic acid pharmacokinetics (trial A) and valproic acid on lacosamide pharmacokinetics (trial B) was investigated in 32 healthy male volunteers, 16 in each trial"><entity charOffset="18-28" id="DDI-PubMed.22162508.s3.e0" text="lacosamide" /><entity charOffset="32-45" id="DDI-PubMed.22162508.s3.e1" text="valproic acid" /><entity charOffset="77-90" id="DDI-PubMed.22162508.s3.e2" text="valproic acid" /><entity charOffset="94-104" id="DDI-PubMed.22162508.s3.e3" text="lacosamide" /><pair ddi="false" e1="DDI-PubMed.22162508.s3.e0" e2="DDI-PubMed.22162508.s3.e0" /><pair ddi="false" e1="DDI-PubMed.22162508.s3.e0" e2="DDI-PubMed.22162508.s3.e1" /><pair ddi="false" e1="DDI-PubMed.22162508.s3.e0" e2="DDI-PubMed.22162508.s3.e2" /><pair ddi="false" e1="DDI-PubMed.22162508.s3.e0" e2="DDI-PubMed.22162508.s3.e3" /><pair ddi="false" e1="DDI-PubMed.22162508.s3.e1" e2="DDI-PubMed.22162508.s3.e1" /><pair ddi="false" e1="DDI-PubMed.22162508.s3.e1" e2="DDI-PubMed.22162508.s3.e2" /><pair ddi="false" e1="DDI-PubMed.22162508.s3.e1" e2="DDI-PubMed.22162508.s3.e3" /><pair ddi="false" e1="DDI-PubMed.22162508.s3.e2" e2="DDI-PubMed.22162508.s3.e2" /><pair ddi="false" e1="DDI-PubMed.22162508.s3.e2" e2="DDI-PubMed.22162508.s3.e3" /></sentence><sentence text=" Volunteers in trial A received valproic acid (300 mg bid) with randomization to either early or late addition of lacosamide (200 mg bid)"><entity charOffset="32-45" id="DDI-PubMed.22162508.s4.e0" text="valproic acid" /><entity charOffset="114-124" id="DDI-PubMed.22162508.s4.e1" text="lacosamide" /><pair ddi="false" e1="DDI-PubMed.22162508.s4.e0" e2="DDI-PubMed.22162508.s4.e0" /><pair ddi="false" e1="DDI-PubMed.22162508.s4.e0" e2="DDI-PubMed.22162508.s4.e1" /></sentence><sentence text=" Those in trial B received lacosamide (200 mg bid) with randomization to either early or late addition of valproic acid (300 mg bid)"><entity charOffset="27-37" id="DDI-PubMed.22162508.s5.e0" text="lacosamide" /><entity charOffset="106-119" id="DDI-PubMed.22162508.s5.e1" text="valproic acid" /><pair ddi="false" e1="DDI-PubMed.22162508.s5.e0" e2="DDI-PubMed.22162508.s5.e0" /><pair ddi="false" e1="DDI-PubMed.22162508.s5.e0" e2="DDI-PubMed.22162508.s5.e1" /></sentence><sentence text=" Area under the concentration-time curve during a 12-hour dosing interval at steady state (AUC(τ,ss)) and maximum steady-state plasma drug concentration (C(max,ss)) were measured for each drug alone and together and tested for equivalence" /><sentence text=" The point estimates (90% confidence intervals) for AUC(τ,ss) and C(max,ss) were 104% (99%-109%) and 101% (97%-107%), respectively, for valproic acid and 100% (98%-103%) and 101% (96%-107%), respectively, for lacosamide, which were within the generally accepted equivalence range of 80% to 125%"><entity charOffset="136-149" id="DDI-PubMed.22162508.s7.e0" text="valproic acid" /><entity charOffset="209-219" id="DDI-PubMed.22162508.s7.e1" text="lacosamide" /><pair ddi="false" e1="DDI-PubMed.22162508.s7.e0" e2="DDI-PubMed.22162508.s7.e0" /><pair ddi="false" e1="DDI-PubMed.22162508.s7.e0" e2="DDI-PubMed.22162508.s7.e1" /></sentence><sentence text=" No changes in the rate or extent of absorption, terminal half-life, or time to maximum concentration were observed" /><sentence text=" These results suggest that lacosamide and valproic acid have no relevant pharmacokinetic drug-drug interaction"><entity charOffset="28-38" id="DDI-PubMed.22162508.s9.e0" text="lacosamide" /><entity charOffset="43-56" id="DDI-PubMed.22162508.s9.e1" text="valproic acid" /><pair ddi="false" e1="DDI-PubMed.22162508.s9.e0" e2="DDI-PubMed.22162508.s9.e0" /><pair ddi="false" e1="DDI-PubMed.22162508.s9.e0" e2="DDI-PubMed.22162508.s9.e1" /></sentence><sentence text="" /></document>